(NASDAQ: KZR) Kezar Life Sciences's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 68.99%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 39.82%.
Kezar Life Sciences's earnings in 2026 is -$61,705,000.On average, 5 Wall Street analysts forecast KZR's earnings for 2026 to be -$25,625,920, with the lowest KZR earnings forecast at -$36,098,765, and the highest KZR earnings forecast at -$6,951,140. On average, 5 Wall Street analysts forecast KZR's earnings for 2027 to be -$19,341,920, with the lowest KZR earnings forecast at -$33,443,389, and the highest KZR earnings forecast at -$538,252.
In 2028, KZR is forecast to generate -$23,322,787 in earnings, with the lowest earnings forecast at -$37,749,405 and the highest earnings forecast at -$538,252.